From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 1m
Viking Therapeutics Data Boosts Hope but Cash Burn Lingers
Viking Therapeutics shows strong VK2735 maintenance data but cash runway remains tight for obesity drug candidate.
In brief
Viking Therapeutics shows strong VK2735 maintenance data but cash runway remains tight for obesity drug candidate. VK2735 maintains 97% weight loss with every-other-week dosing after induction. Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
VK2735 Maintenance Data
Patients maintaining up to 97% of weight loss after induction with every-other-week dosing.
“Patients who switched to every-other-week maintenance dosing maintained up to 97% of body-weight reduction achieved during induction.”
Q2 2026 Financials
Reported $128.1 million net loss versus $65.6 million in Q2 2025 with rising R&D spending.
Cash Position
Cash and short-term investments at $501.7 million as of June 30, 2026, down from $706 million in December 2025.
VANQUISH Trial Progress
VANQUISH-1 enrolled over 4,500 patients and VANQUISH-2 over 1,000 patients ahead of schedule.
Oral Formulation Plan
Planned Phase 3 oral VK2735 study beginning in Q4 2026 to improve patient access.
Investor Watchpoints
Phase 3 enrollment, oral formulation results, and cash runway critical for next steps.
In short
VK2735 maintains 97% weight loss with every-other-week dosing after induction.
